		Equivalent of Form PTO/SB/08a (07-0		
Substitute for form 1449/PTO	Complete if Known			
	Application Number	10/551,466		
FIRST SUPPLEMENTAL	§ 371(c) Date:	August 7, 2006		
INFORMATION DISCLOSURE	First Named Inventor	Ji Hoon JEONG		
	Art Unit	1635		
STATEMENT BY APPLICANT (Use as many sheets as necessary)	Examiner Name	Pitrak, Jennifer K.		
Sheet 1 of 1	Attorney Docket Number	2229.0020000/JUK/SMW/X-S		

	U.S. PATENT DOCUMENTS				
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
initials*	No.1	Number-Kind Code ² (1f known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	US5	2004/0167090 A1	08-26-2004	Monahan et al.	
	US6	2004/0266707 A1	12-30-2004	Leake et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner Foreign Patent Document Pr		Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	т6	
initials*	Cite No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Figures Appear	'
	FP2	WO 2004/009769 A2	01-29-2004	Tolentino et al.		
	FP3	WO 2004/076630 A2	09-10-2004	Monahan et al.		
	FP4	WO 2004/087931 A1	10-14-2004	Jeong et al.		
	FP5	EP 1 801 210 A1	06-27-2007	Nagasaki et al.		
					1	

1302472_1.DOC

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and **EA-MANIERS: MITHAL IT REVERDE CONSIGERAL, Whether or not citation is an contromance with MPLF 093. Draw line through citation if not in contomance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number obligants of the Codes of USPTO Patent Documents at wow, usgot goo or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the riego of the Emperor must proceed the serial number of the applicant is of document. *Vind the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

Sheet

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/551,466			
§ 371(c) Date:	August 7, 2006			
First Named Inventor	Ji Hoon JEONG			
Art Unit	1635			
Examiner Name	Pitrak, Jennifer K.			
Attorney Docket Number	2229.0020000/JUK/SMW/X-S			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL4	BONORA, "Polymer-conjugated Bioactive Oligonucleotides," <i>Journal of Bioactive and Compatible Polymers 17</i> :375-389 (September 2002) Sage Publications	
	NPL5	HEALY et al., "Pharmacokinetics and Biodistribution of Novel Aptamer Compositions," Pharmaceutical Research 21:2234-2246 (2004) Springer Science+Business Media, Inc.	
	NPL6	JEONG et al., "Novel Intracellular Delivery System of Antisense Oligonucleotide by Self-Assembled Hybrid Micelles Composed of DNA/PEG Conjugate and Cationic Fusogenic Peptide," Bioconjugate Chem. 14:473-479 (March 2003) American Chemical Society	
	NPL7	JEONG et al., "A New Antisense Oligonucleotide Delivery System Based on Self-Assembled ODN-PEG Hybrid Conjugate Micelles," Journal of Controlled Release 93:183-191 (December 2003) Elsevier B.V.	
	NPL8	JONES et al., "Conjugates of Double-Stranded Oligonucleotides with Poly(ethylene glycol) and Keyhole Limpet Hemocyanin: A Model for Treating Systemic Lupus Erythematosus," Bioconjugate Chem. 5:390-399 (1994) American Chemical Society	
	NPL9	KAWAGUCHI et al., "Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly(ethylene glycol)," Biol. Pharm. Bull. 18:474-476 (1995) Pharmaceutical Society of Japan	
	NPL10	KIM et al., "Target-Specific Gene Silencing by siRNA Plasmid DNA Complexed with Folate-Modified Poly(ethylenimine)," Journal of Controlled Release 104:223-232 (2005) Elsevier B.V.	
	NPL11	KIM et al., "PEG conjugated VEGF siRNA for anti-angiogenic gene therapy," Journal of Controlled Release 116:123-129 (2006) Elsevier B.V.	
	NPL12	LEE et al., "Intracellular siRNA Delivery System Using Polyelectrolyte Complex Micelles Prepared from VEGF siRNA-PEG Conjugate and Cationic Fusogenic Peptide," Biochemical and Biophysical Research Communications 357:511-516 (2007) Elsevier Inc.	

MON BARROW I STORE DOCUMENTS

Examiner Signature	Date Considered	

"EXAMINER: nittal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

not considered include copy of this form with rest communication to appraism.

"Applicant's unique cation designation number (optional)." Applicant is unique cation designation number (optional)." Applicant is unique cation designation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application confiderability is operated by 38 U.S. CT22 and 37 CFR 1.41. This collection is esterated to tast 2-bours to complete, including gathering, preparing, and submitting the completed application form to be USFTO. Times will vary depending upon the beautiful comments on the amount of time by unique to complete this form and/or suggestions for reducing between the Discontinuous Comments on the amount of time by unique to complete this form and/or suggestions for reducing between the Discontinuous Comments on the amount of time by unique to complete this form and/or suggestions for reducing between the Discontinuous Comments on the ADD Commission of the Comments of the ADD Commission of the Comments of the ADD Commission of the Comments of the ADD Commission of t

Substitute for form 1449/PTO

Sheet

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

2

(Use as many sheets as necessary) of

Complete if Known			
Application Number	10/551,466		
§ 371(c) Date:	August 7, 2006		
First Named Inventor	Ji Hoon JEONG		
Art Unit	1635		
Examiner Name	Pitrak, Jennifer K.		
Attorney Docket Number 2229.0020000/JUK/SMW/X			

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*			T ²		
	NPL13	OISHI et al., "Smart Polyion Complex Micelles for Targeted Intracellular Delivery of PEGylated Antisense Oligonucleotides Containing Acid-Labile Linkages," ChemBioChem 6:718-725 (2005) Wiley-VCH Verlag GmbH & Co. Weinheim			
	OISHI et al., "Lactosylated Poly(ethylene glycol)-siRNA Conjugate Acid-Labile β-Thiopropionate Linkage to Construct pH-Sensitive Po Complex Micelles Achieving Enhanced Gene Silencing in Hepatoms Am. Chem. Soc. 127:1624-1625 (2005) American Chemical Society				

1302425.1

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

Applicant's unique citation designation number (optionise). Applicant is to become the property of the propert including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.